Clinical Study
Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?
Table 4
Details of multivariate analysis for overall survival.
| Variable | Hazard ratio | value on Cox regression analysis |
| | >100 (0.0–NA) | 0.980 |
| ECOG PS | 0.321 (0.078–1.322) | 0.116 |
| Smoking status | 1.709 (0.475–6.153) | 0.412 |
| Brain metastasis | 0.844 (0.176–4.042) | 0.832 |
| EGFR mutation type | 0.361 (0.090–1.439) | 0.149 |
| Treatment received after failure on pemetrexed-carboplatin | 0.265 (0.060–1.163) | 0.078 |
|
|
was defined as age of 65 years or above. NA: not applicable.
|